Foldax Presents at the 2021 Transcatheter Valve Technologies Meeting
July 29, 2021
Last week, Foldax presented on the company’s innovative Tria valve at the 2021 Transcatheter Valve Technologies (TVT) meeting. View the slides HERE.
The presentation titled “Foldax Biopolymer Valves: An Alternative to Tissue Based Leaflet Valves” was given by Foldax investigator, Dr. David Heimansohn, chief of surgery at St. Vincent/Ascension in Indiana and was well received. During his talk he detailed the Tria technology and the excellent hemodynamic results from its US Aortic Surgical Early Feasibility Study (EFS).
The aortic EFS is the first in a series of clinical studies Foldax will be conducting on its Tria LifePolymer heart valve line.
Tria™ heart valves are made with revolutionary new LifePolymer™ material and designed to last a lifetime. Our goal is to help millions of patients with aortic, mitral, and tricuspid valve disease receive cost-effective treatment in a single heart valve procedure.
“The Q&A session following the presentation showed a lot of interest in Tria LifePolymer valves as the wave of the future,” said Mike Numamoto, vice president of marketing for Foldax.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
